https://www.yiliao.com/index.php?action=history&feed=atom&title=ROS1_%E6%BF%80%E9%85%B6%E7%BB%93%E6%9E%84%E5%9F%9F%E7%AA%81%E5%8F%98
ROS1 激酶结构域突变 - 版本历史
2026-04-20T08:19:39Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=ROS1_%E6%BF%80%E9%85%B6%E7%BB%93%E6%9E%84%E5%9F%9F%E7%AA%81%E5%8F%98&diff=315637&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-25T01:49:08Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>ROS1 激酶结构域突变</strong>（ROS1 Kinase Domain Mutations）是指在 <strong>[[ROS1]]</strong> 融合阳性 <strong>[[非小细胞肺癌]]</strong>（NSCLC）患者接受靶向治疗（尤其是第一代药物 <strong>[[克唑替尼]]</strong>）后，肿瘤细胞为逃避药物抑制而发生的获得性<strong>[[耐药突变]]</strong>。由于 ROS1 与 <strong>[[ALK]]</strong> 的激酶结构域具有高度同源性（约 77%），两者的耐药突变谱也非常相似。最常见的耐药突变是位于<strong>[[溶剂前沿]]</strong>的 <strong>[[G2032R]]</strong>（约占耐药病例的 40%），它会导致第一代和部分第二代药物失效。新一代大环内酰胺类抑制剂（如 <strong>[[瑞波替尼]]</strong>、<strong>[[他雷替尼]]</strong>）的设计初衷正是为了克服这一顽固突变。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">ROS1 Mutations</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Acquired Resistance (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[Image:ROS1_G2032R_mutation_structure.png]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">G2032R：ROS1 的“G1202R”</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">涉及基因</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[ROS1]]</strong> (6q22)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">发生背景</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">TKI 治疗进展后</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">最常见突变</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[G2032R]]</strong> (溶剂前沿)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">守门员突变</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[L2026M]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">一代药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[克唑替尼]]</strong>, <strong>[[恩沙替尼]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">新一代药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[瑞波替尼]]</strong>, [[洛拉替尼]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">其他机制</th><br />
<td style="padding: 6px 12px; color: #0f172a;">旁路激活 (KRAS, EGFR)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">突变全景：从 G2032R 说起</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
ROS1 的突变位点与 ALK 高度对应。由于克唑替尼最初是为 MET 设计的，后来发现对 ALK 和 ROS1 有效，因此这三个激酶的耐药位点（如溶剂前沿区）也表现出惊人的一致性。<br />
</p><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: center;"><br />
<tr style="background-color: #eff6ff; color: #1e40af;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 15%;">突变位点</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 20%;">功能分类</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 25%;">克唑替尼<br>恩曲替尼</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 20%;">洛拉替尼<br>(3代)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 20%;">瑞波替尼<br>他雷替尼</th><br />
</tr><br />
<tr style="background-color: #f8fafc; font-weight: bold; text-align: left;"><br />
<td colspan="5" style="padding: 8px 12px; border: 1px solid #cbd5e1; color: #64748b;">I. 溶剂前沿突变 (最常见)</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #b91c1c;"><strong>[[G2032R]]</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">对应 ALK G1202R</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #fee2e2; color: #b91c1c;">高度耐药</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #fef9c3; color: #854d0e;">中等/耐药</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;"><strong>敏感</strong></td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">D2033N</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">溶剂前沿</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #fee2e2; color: #b91c1c;">耐药</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">敏感</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">敏感</td><br />
</tr><br />
<tr style="background-color: #f8fafc; font-weight: bold; text-align: left;"><br />
<td colspan="5" style="padding: 8px 12px; border: 1px solid #cbd5e1; color: #64748b;">II. 守门员突变 (Gatekeeper)</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[L2026M]]</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">对应 ALK L1196M</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #fee2e2; color: #b91c1c;">耐药</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">敏感</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">敏感</td><br />
</tr><br />
<tr style="background-color: #f8fafc; font-weight: bold; text-align: left;"><br />
<td colspan="5" style="padding: 8px 12px; border: 1px solid #cbd5e1; color: #64748b;">III. 其他位点</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">S1986Y/F</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">对应 ALK C1156Y</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #fee2e2; color: #b91c1c;">耐药</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">敏感</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">敏感</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心耐药机制：G2032R</h2><br />
<div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">最难攻克的堡垒</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
<strong>G2032R</strong> 是 ROS1 阳性患者使用克唑替尼后最常见的突变。其机制是位于 <strong>[[ATP结合口袋]]</strong> 溶剂前沿的甘氨酸（Gly, G）突变为精氨酸（Arg, R）。精氨酸巨大的侧链和正电荷产生了强烈的<strong>[[空间位阻]]</strong>和静电排斥，直接把克唑替尼和<strong>[[恩曲替尼]]</strong>“挤”出了结合位点。<br />
</p><br />
</div><br />
[Image:Mechanism_of_ROS1_G2032R_resistance.png]<br />
<br />
<h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">新一代药物的突破</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
针对 G2032R，新一代 ROS1 抑制剂采用了独特的设计策略：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[瑞波替尼]] (Repotrectinib)：</strong><br />
<br>一种大环内酰胺类抑制剂。它的分子结构比较紧凑（大环结构），能够精确地折叠进突变后的结合口袋，避开 G2032R 的位阻。临床数据显示，其对 G2032R 突变患者具有显著疗效，已获 FDA 批准。</li><br />
<li style="margin-bottom: 12px;"><strong>[[他雷替尼]] (Taletrectinib)：</strong><br />
<br>另一种高效的 ROS1/NTRK 抑制剂，对 G2032R 同样表现出优异的抑制活性，且脑透过率高，目前处于后期临床开发阶段。</li><br />
<li style="margin-bottom: 12px;"><strong>[[洛拉替尼]] (Lorlatinib)：</strong><br />
<br>虽然是 ALK 的三代药，但它对 ROS1 G2032R 的活性较弱（与 ALK G1202R 的高度敏感形成对比）。因此，在 ROS1 领域，洛拉替尼主要用于其他非 G2032R 的耐药突变。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Shaw AT, et al. (2019).</strong> <em>Crizotinib in ROS1-rearranged non-small-cell lung cancer.</em> <strong>[[New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[奠基之作]：确立了克唑替尼作为 ROS1 阳性肺癌一线治疗的标准地位，但也指出了耐药不可避免的问题。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Gainor JF, et al. (2017).</strong> <em>Molecular mechanisms of resistance to crizotinib in ROS1-positive lung cancer.</em> <strong>[[JCO Precision Oncology]]</strong>.<br><br />
<span style="color: #475569;">[机制解析]：通过对耐药患者样本的测序，首次确认 G2032R 是 ROS1 最主要的耐药突变，并指出了其对 Lorlatinib 的不敏感性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Drilon A, et al. (2024).</strong> <em>Repotrectinib in ROS1-Fusion-Positive Non-Small-Cell Lung Cancer.</em> <strong>[[New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[TRIDENT-1研究]：证实了瑞波替尼在 TKI 经治（含 G2032R 突变）患者中具有同类最佳（Best-in-class）的疗效，推动了新药上市。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
ROS1 突变 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联基因</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[ALK]]</strong> (同源性高) • <strong>[[NTRK]]</strong> (结构相似)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心突变</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[G2032R]]</strong> (溶剂前沿) • [[L2026M]] (守门员)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">一代药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[克唑替尼]] • [[恩曲替尼]] (入脑好)</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">下一代药物</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[瑞波替尼]]</strong> • [[他雷替尼]] (AB-106)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020